<![CDATA[RubrYc Therapeutics, Inc. 보도자료 - 뉴스와이어]]>https://www.newswire.co.kr/?md=A10&act=article&no=37470>Thu, 23 Apr 2026 01:17:27 +0900Copyright (c) 2004~2026 Korea Newswire All rights reservedko-KR<![CDATA[RubrYc Therapeutics Announces Series A2 Preferred Equity Financing, Collaboration, and RTX-003 License with iBio, Inc.]]>https://www.newswire.co.kr/newsRead.php?no=929368Thu, 26 Aug 2021 17:40:00 +0900<![CDATA[RubrYc 테라퓨틱스, 아이바이오와 시리즈A2 우선주 파이낸싱, 협업 및 RTX-003 라이선스 발표]]>https://www.newswire.co.kr/newsRead.php?no=929369Thu, 26 Aug 2021 17:40:00 +0900<![CDATA[RubrYc Therapeutics Announces a Research Collaboration and License Option Agreement With Zai Labs]]>https://www.newswire.co.kr/newsRead.php?no=921589Wed, 14 Apr 2021 17:40:00 +0900<![CDATA[RubrYc 테라퓨틱스, 자이 랩스와 연구 협력 및 라이선스 옵션 계약 체결]]>https://www.newswire.co.kr/newsRead.php?no=921590Wed, 14 Apr 2021 17:40:00 +0900